Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Natera Announces Achievement of Key Recruitment Milestones in ProActive Study and Success in Prospera™ Early Access Program
01:03pm, Monday, 04'th May 2020
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the achievement of key recruitment milestones in the ProActive registry study and success in the Pros
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
What will the Oracle say?
09:05am, Friday, 01'st May 2020
News is free at Seeking Alpha.This post is a Notable Call. Notable Calls are a Premium feature.To access this and other Notable Calls, try a free trial to Seeking Alpha Premium.
Natera Announces First Quarter 2020 Earnings Conference Call
01:03pm, Wednesday, 29'th Apr 2020
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2020, after the market close on Ma
Assenagon Asset Management S.A. Takes Position in Natera Inc (NASDAQ:NTRA)
08:36am, Saturday, 25'th Apr 2020
Assenagon Asset Management S.A. bought a new stake in Natera Inc (NASDAQ:NTRA) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commis
Natera: This Molecular Diagnostic Player Is A Solid Pick In April 2020
06:51pm, Friday, 24'th Apr 2020
Natera has a diversified portfolio of molecular diagnostic tests. The company has a robust financial portfolio. Investors should consider risks such as COVID-19
CareDx: A Robust Transplant Diagnostics Pick For 2020
08:47pm, Thursday, 23'rd Apr 2020
CareDx is targeting the medically essential stem cell and organ transplant market. The company has a robust financial profile. Investors, however, should be awa
Natera (NASDAQ:NTRA) Upgraded by BidaskClub to "Buy"
09:50am, Thursday, 23'rd Apr 2020
Natera (NASDAQ:NTRA) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Thursday, BidAskClub reports. A number of other equities analyst
Naturally Splendid Enterprises (CVE:NSP) Trading Down 14.3%
08:54am, Wednesday, 22'nd Apr 2020
Naturally Splendid Enterprises Ltd (CVE:NSP)’s stock price dropped 14.3% on Monday . The company traded as low as C$0.03 and last traded at C$0.03, approximately 232,140 shares were traded during mi
CareDx CEO Says Pandemic Proves Value Of Remote Transplant Monitoring System
09:05pm, Tuesday, 21'st Apr 2020
One outcome from the coronavirus pandemic could be the adoption of CareDx Inc (NASDAQ: CDNA)’s management platform for organ transplant patients.
“This...
Natera Inc (NASDAQ:NTRA) Shares Sold by Macquarie Group Ltd.
11:00am, Monday, 20'th Apr 2020
Macquarie Group Ltd. reduced its stake in shares of Natera Inc (NASDAQ:NTRA) by 6.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,881,170 shares of the medical research compa
620,148 Shares in Natera Inc (NASDAQ:NTRA) Purchased by Norges Bank
09:32am, Saturday, 18'th Apr 2020
Norges Bank purchased a new position in Natera Inc (NASDAQ:NTRA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institut
Natera (NASDAQ:NTRA) Earns "Buy" Rating from Canaccord Genuity
05:44am, Saturday, 18'th Apr 2020
Canaccord Genuity restated their buy rating on shares of Natera (NASDAQ:NTRA) in a research report released on Wednesday morning, TipRanks reports. The firm currently has a $46.00 target price on the
Exchange Traded Concepts LLC Purchases 1,603 Shares of Natera Inc (NASDAQ:NTRA)
09:34am, Thursday, 16'th Apr 2020
Exchange Traded Concepts LLC increased its position in Natera Inc (NASDAQ:NTRA) by 61.8% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,196 shares of the medical resea
BRIEF-Natera Asserts Three New Oncology Patents Against Archerdx
01:29pm, Wednesday, 15'th Apr 2020
Natera Inc:
